Spots Global Cancer Trial Database for prostate neoplasms
Every month we try and update this database with for prostate neoplasms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Far Infrared Radiation Treatment for Prostate Cancer | NCT00573820 | Prostatic Neopl... | Far Infrared Ra... | - | GAAD Medical Research Institute Inc. | |
| Use of Tracking Devices to Locate Abnormalities During Invasive Procedures | NCT00102544 | Adenocarcinoma Prostate Neopla... Prostate Cancer Renal Cell Carc... Von Hippel Lind... | EM Tracking | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer | NCT00142506 | Prostate Cancer Erectile Dysfun... | sildenafil citr... placebo tablets... | - | Memorial Sloan Kettering Cancer Center | |
| A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057 | NCT02916537 | Prostate Cancer | CTT1057 Prostatectomy | 18 Years - | Cancer Targeted Technology | |
| A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT00910754 | Prostate Neopla... | Abiraterone ace... Prednisone | 18 Years - | Janssen Research & Development, LLC | |
| Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer | NCT00657904 | Non-metastatic ... | Bicalutamide Placebo | 18 Years - | AstraZeneca | |
| A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01424930 | Prostate Neopla... Prostate Cancer | Abiraterone Prednisone | 18 Years - | Janssen-Ortho Inc., Canada | |
| A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01017939 | Prostate Neopla... | Abiraterone ace... Prednisone Dextromethorpha... Theophylline | 18 Years - | Janssen Research & Development, LLC | |
| An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma | NCT00544440 | Prostate Neopla... | Abiraterone ace... Prednisone | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01834209 | Prostate Neopla... | Abiraterone ace... Prednisone or p... | 18 Years - | Janssen Research & Development, LLC | |
| Novel Therapy Target in Metastatic Prostate Cancer | NCT05577689 | Prostate Neopla... | Tissue | 18 Years - | Fudan University | |
| A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer | NCT00972309 | Prostate Specif... Prostate Neopla... | T-cell receptor... T-cell receptor... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution | NCT00643994 | Prostate Cancer Prostatic Cance... Prostate Neopla... Prostatic Neopl... Cancer of the P... | CyberKnife Ster... | 18 Years - | Accuray Incorporated | |
| Use of Tracking Devices to Locate Abnormalities During Invasive Procedures | NCT00102544 | Adenocarcinoma Prostate Neopla... Prostate Cancer Renal Cell Carc... Von Hippel Lind... | EM Tracking | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Prostate Cancer Stereotactic Radiotherapy | NCT02319239 | Prostate Neopla... Toxicity Due to... | Fractionation hypofractionate... stereotactic fr... | 30 Years - | Tampere University Hospital | |
| Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy | NCT03388619 | Cancer Of Prost... Prostate Neopla... Prostate Cancer Neoplasms of Pr... Prostatic Cance... | Prostate bed wi... Prostate bed ir... Whole Body Bone... 18F-NaF PET Ima... CT mpMRI ADT | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01017939 | Prostate Neopla... | Abiraterone ace... Prednisone Dextromethorpha... Theophylline | 18 Years - | Janssen Research & Development, LLC | |
| A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients | NCT01284920 | Prostate Cancer Prostate Neopla... Castration Resi... | MDV3100 | 20 Years - | Astellas Pharma Inc | |
| Fusion Guided Focal Laser Ablation of Prostate Cancer | NCT02759744 | Prostate Cancer Prostate Neopla... | ultrasound imag... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| PS-341 Followed by Removal of Prostate for Those With Prostate Cancer | NCT00425503 | Prostate Neopla... | PS-341 (bortezo... | 18 Years - | Baylor College of Medicine | |
| Prostate Cancer Symptom Management for Low Literacy Men | NCT00983710 | Prostate Cancer | PC-PEP - Prosta... Usual care | 18 Years - | Baylor College of Medicine | |
| PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | NCT03685591 | Breast Neoplasm... Prostate Neopla... Neoplasms, Squa... Melanoma Mesothelioma Pancreatic Neop... Colorectal Neop... Carcinoma, Rena... Liver Neoplasms | PF-06952229 Enzalutamide | 18 Years - | Pfizer | |
| Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer | NCT01581749 | Prostate Neopla... | "TrueBeam" ster... | 21 Years - | Main Line Health | |
| An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy | NCT00474383 | Prostate Neopla... | Abiraterone ace... Glucocorticoid | 18 Years - | Cougar Biotechnology, Inc. | |
| An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma | NCT00544440 | Prostate Neopla... | Abiraterone ace... Prednisone | 18 Years - | Janssen Research & Development, LLC | |
| 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer | NCT03181867 | Prostate Neopla... Prostatic Cance... Prostate Cancer Cancer Of Prost... Metastatic Pros... | 18F-DCFPyL 18F-FDG PSMA-11 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients | NCT01284920 | Prostate Cancer Prostate Neopla... Castration Resi... | MDV3100 | 20 Years - | Astellas Pharma Inc | |
| Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer | NCT01581749 | Prostate Neopla... | "TrueBeam" ster... | 21 Years - | Main Line Health | |
| Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer | NCT00970203 | Cancer of Prost... Cancer of the P... Neoplasms, Pros... Neoplasms, Pros... Prostate Cancer Prostate Neopla... Prostatic Cance... | androgen ablati... DC1 vaccine | 18 Years - | Roswell Park Cancer Institute | |
| Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer | NCT00657904 | Non-metastatic ... | Bicalutamide Placebo | 18 Years - | AstraZeneca | |
| Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer | NCT00142506 | Prostate Cancer Erectile Dysfun... | sildenafil citr... placebo tablets... | - | Memorial Sloan Kettering Cancer Center | |
| Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment | NCT03531827 | Metastatic Cast... Prostate Neopla... | enzalutamide CRLX101 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Optimized 2D-RT for Prostate Cancer | NCT03339531 | Prostate Cancer | 2D radiotherapy | 18 Years - 79 Years | IRCCS Azienda Ospedaliero-Universitaria di Bologna | |
| Sipuleucel-T Manufacturing Demonstration Study | NCT01477749 | Cancer of Prost... Cancer of the P... Neoplasms, Pros... Neoplasms, Pros... Prostate Cancer Prostate Neopla... Prostatic Cance... | sipuleucel-T | 18 Years - | Dendreon | |
| Casodex vs Placebo in Non-Metastatic Early Prostate Cancer | NCT00672282 | Non-Metastatic ... | Bicalutamide Placebo | 18 Years - | AstraZeneca | |
| A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT00910754 | Prostate Neopla... | Abiraterone ace... Prednisone | 18 Years - | Janssen Research & Development, LLC | |
| Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer | NCT00970203 | Cancer of Prost... Cancer of the P... Neoplasms, Pros... Neoplasms, Pros... Prostate Cancer Prostate Neopla... Prostatic Cance... | androgen ablati... DC1 vaccine | 18 Years - | Roswell Park Cancer Institute | |
| High Dose Rate Prostate Brachytherapy: Dose Escalation to Dominant Intra-prostatic Nodule | NCT01605097 | Prostate Cancer | HDR interstitia... | 40 Years - 80 Years | British Columbia Cancer Agency | |
| Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer | NCT01217697 | Prostate Neopla... Genital Neoplas... Urogenital Neop... Genital Disease... | Abiraterone Ace... Prednisone\Pred... | 18 Years - 99 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Novel Therapy Target in Metastatic Prostate Cancer | NCT05577689 | Prostate Neopla... | Tissue | 18 Years - | Fudan University | |
| Prostate Cancer Stereotactic Radiotherapy | NCT02319239 | Prostate Neopla... Toxicity Due to... | Fractionation hypofractionate... stereotactic fr... | 30 Years - | Tampere University Hospital | |
| (Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer | NCT00673205 | Non-Metastatic ... | Bicalutamide Placebo | 18 Years - | AstraZeneca | |
| CyberKnife Radiosurgery for Localized Prostatic Carcinoma | NCT01045148 | Prostate Cancer | CyberKnife Radi... CyberKnife Radi... | 18 Years - | CyberKnife Centers of San Diego | |
| Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer | NCT02334579 | Prostate Cancer Prostatic Cance... Prostate Neopla... Prostatic Neopl... Cancer of the P... | CyberKnife Ster... | 18 Years - | Swedish Medical Center | |
| RecoverPC: Relugolix vs GnRH Agonist in Quality of Life | NCT05765500 | Prostate Cancer Prostatic Neopl... | Relugolix Leuprolide | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Anatomic Nerve Sparing Radical Perineal Prostatectomy | NCT00922818 | Prostate Cancer | 18 Years - | Maimonides Medical Center | ||
| Far Infrared Radiation Treatment for Prostate Cancer | NCT00573820 | Prostatic Neopl... | Far Infrared Ra... | - | GAAD Medical Research Institute Inc. | |
| CyberKnife Radiosurgery for Localized Prostatic Carcinoma | NCT01045148 | Prostate Cancer | CyberKnife Radi... CyberKnife Radi... | 18 Years - | CyberKnife Centers of San Diego | |
| M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer | NCT04633252 | Cancer Of Prost... Prostate Neopla... | ADT Prednisone M7824 Docetaxel M9241 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Quinacrine Treatment in Patients With Androgen-Independent Prostate Cancer | NCT00417274 | Prostatic Cance... | Quinacrine | 18 Years - | Cleveland BioLabs | |
| Sipuleucel-T Manufacturing Demonstration Study | NCT01477749 | Cancer of Prost... Cancer of the P... Neoplasms, Pros... Neoplasms, Pros... Prostate Cancer Prostate Neopla... Prostatic Cance... | sipuleucel-T | 18 Years - | Dendreon | |
| Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer | NCT01692483 | Prostate Neopla... | Abiraterone ace... Prednisone | 18 Years - | Janssen Pharmaceutica | |
| CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry | NCT00643617 | Prostate Cancer Prostatic Cance... Prostatic Neopl... Prostate Neopla... Cancer of the P... | CyberKnife Ster... CyberKnife Ster... | 18 Years - | Accuray Incorporated | |
| An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001 | NCT01664728 | Prostate Neopla... | Abiraterone ace... Glucocorticoid | 18 Years - | Janssen Research & Development, LLC | |
| A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer | NCT01228760 | Prostate Neopla... | ASG-5ME | 18 Years - | Astellas Pharma Inc | |
| 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer | NCT03181867 | Prostate Neopla... Prostatic Cance... Prostate Cancer Cancer Of Prost... Metastatic Pros... | 18F-DCFPyL 18F-FDG PSMA-11 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Fusion Guided Focal Laser Ablation of Prostate Cancer | NCT02759744 | Prostate Cancer Prostate Neopla... | ultrasound imag... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | NCT01715285 | Prostate Neopla... | Abiraterone ace... Prednisone Androgen depriv... Abiraterone ace... Prednisone Plac... | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer | NCT01946204 | Prostatic Neopl... | Apalutamide Placebo | 18 Years - | Aragon Pharmaceuticals, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
